OBJECTIVES: To elucidate why the virulence of HIV-1 and HIV-2 infections differ in West African populations. STUDY DESIGN/ METHOD: Peripheral blood plasma virion RNA and cellular proviral DNA levels were measured in a cross-section of 59 HIV-1 and 49 HIV-2 singly infected individuals representing all stages of infection in The Gambia, West Africa. Novel reverse transcriptase polymerase chain reaction (RT-PCR) assays specific and sensitive for virus quantification of non-clade B HIV-1 and HIV-2 infections were used. RESULTS: HIV-1 and HIV-2 proviral and plasma RNA levels were inversely correlated with CD4+ count for both infections with cellular proviral load similar at each stage of infection. Critically, up to three-fourths of HIV-2-infected individuals with high CD4 percentages (> 28%) had undetectable (< 500 copies/mL) levels of peripheral blood HIV-2 RNA in contrast to HIV-1-infected individuals who had readily detectable plasma virus at all stages of infection (P < .0001). Plasma RNA levels were similar in the intermediate and end stages of infection, indicating similar replication potential for both viruses. In the cross-section of HIV-1- and HIV-2-infected patients studied, the data indicate a wider dynamic range of HIV-2 RNA in vivo compared with HIV-1. DISCUSSION: Low levels of HIV-2 replication and virion expression characterize individuals with high CD4+ lymphocyte counts, suggesting that a very different dynamic equilibrium exists between virus and host for HIV-2 compared with HIV-1. By analogy with HIV-1, our data implicate a considerably lower turnover of HIV-2 virion RNA in vivo with a markedly reduced production of infectious genomes in individuals during the subclinical phase of infection. CONCLUSION: The lower levels of virion expression of HIV-2 infections in vivo are compatible with observed differences in the natural history of HIV-1 and HIV-2 infections, relating to overall differences in the pathogenesis and disease progression of the two infections.
OBJECTIVES: To elucidate why the virulence of HIV-1 and HIV-2 infections differ in West African populations. STUDY DESIGN/ METHOD: Peripheral blood plasma virion RNA and cellular proviral DNA levels were measured in a cross-section of 59 HIV-1 and 49 HIV-2 singly infected individuals representing all stages of infection in The Gambia, West Africa. Novel reverse transcriptase polymerase chain reaction (RT-PCR) assays specific and sensitive for virus quantification of non-clade B HIV-1 and HIV-2 infections were used. RESULTS:HIV-1 and HIV-2 proviral and plasma RNA levels were inversely correlated with CD4+ count for both infections with cellular proviral load similar at each stage of infection. Critically, up to three-fourths of HIV-2-infected individuals with high CD4 percentages (> 28%) had undetectable (< 500 copies/mL) levels of peripheral blood HIV-2 RNA in contrast to HIV-1-infected individuals who had readily detectable plasma virus at all stages of infection (P < .0001). Plasma RNA levels were similar in the intermediate and end stages of infection, indicating similar replication potential for both viruses. In the cross-section of HIV-1- and HIV-2-infectedpatients studied, the data indicate a wider dynamic range of HIV-2 RNA in vivo compared with HIV-1. DISCUSSION: Low levels of HIV-2 replication and virion expression characterize individuals with high CD4+ lymphocyte counts, suggesting that a very different dynamic equilibrium exists between virus and host for HIV-2 compared with HIV-1. By analogy with HIV-1, our data implicate a considerably lower turnover of HIV-2 virion RNA in vivo with a markedly reduced production of infectious genomes in individuals during the subclinical phase of infection. CONCLUSION: The lower levels of virion expression of HIV-2 infections in vivo are compatible with observed differences in the natural history of HIV-1 and HIV-2 infections, relating to overall differences in the pathogenesis and disease progression of the two infections.
Authors: Ninon Taylor; Jan Marco Kern; Wolfgang Prammer; Alois Lang; Bernhard Haas; Martin Gisinger; Robert Zangerle; Alexander Egle; Richard Greil; Hannes Oberkofler; Josef Eberle Journal: Wien Klin Wochenschr Date: 2014-01-18 Impact factor: 1.704
Authors: Mohammad Khalid; Hangxing Yu; Daniel Sauter; Shariq M Usmani; Jan Schmokel; Jerome Feldman; Rob A Gruters; Marchina E van der Ende; Matthias Geyer; Sarah Rowland-Jones; Albert D Osterhaus; Frank Kirchhoff Journal: J Virol Date: 2012-02-15 Impact factor: 5.103
Authors: Roseanne C Wilkinson; Claire K Murrell; Rebecca Guy; Gail Davis; Joanna M Hall; David C North; Nicola J Rose; Neil Almond Journal: J Virol Date: 2003-10 Impact factor: 5.103
Authors: Maarten F Schim van der Loeff; Natasha Larke; Steve Kaye; Neil Berry; Koya Ariyoshi; Abraham Alabi; Carla van Tienen; Aleksandra Leligdowicz; Ramu Sarge-Njie; Zacharias da Silva; Assan Jaye; Dominique Ricard; Tim Vincent; Sarah Rowland Jones; Peter Aaby; Shabbar Jaffar; Hilton Whittle Journal: Retrovirology Date: 2010-05-19 Impact factor: 4.602
Authors: Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa Journal: PLoS Pathog Date: 2009-11-20 Impact factor: 6.823